<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Allogeneic stem cell transplantation (SCT) is the treatment of choice for young patients (age â‰¤ 55 years) with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) characterized by poor-risk or intermediate-risk cytogenetics, who have a histocompatible related or unrelated donor </plain></SENT>
<SENT sid="1" pm="."><plain>For patients who lack an human leukocyte antigen-compatible donor, autologous SCT, or chemotherapy may be good alternatives for those with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and with good-risk cytogenetic characteristics </plain></SENT>
<SENT sid="2" pm="."><plain>Iron toxicity is an underestimated cause of hematopoietic stem cell transplantation (HSCT) treatment-related mortality </plain></SENT>
<SENT sid="3" pm="."><plain>The pathogenesis, diagnosis, and monitoring of iron-induced organ damage are currently topics of investigation </plain></SENT>
<SENT sid="4" pm="."><plain>Prospective studies on the prevention or treatment of iron toxicity before HSCT and/or after HSCT are necessary </plain></SENT>
</text></document>